

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



JW (Cayman) Therapeutics Co. Ltd

藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

**VOLUNTARY ANNOUNCEMENT
STRATEGIC PARTNERSHIP WITH 2SEVENTY BIO, INC.**

Reference is made to the announcement of JW (Cayman) Therapeutics Co. Ltd (the “**Company**” or “**JW Therapeutics**”) dated September 12, 2023 in relation to a potential further strategic partnership with 2seventy bio, Inc (“**2seventy bio**”) (NASDAQ: TSVT) (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as defined in the Announcement.

This announcement is made by the Company on a voluntary basis to provide an update to the shareholders and potential investors of the Company with respect to a recent business development. The board of directors (the “**Board**”) of the Company is pleased to announce that on January 1, 2024, the Company entered into an exclusive collaboration agreement (the “**Collaboration Agreement**”) with 2seventy bio for the co-development and commercialization of a chimeric antigen receptor (“**CAR**”) T cell therapy product (the “**Product**”) for autoimmune diseases (the “**AID program**”) in Greater China. The strategic alliance is an expansion of the partnership that was established in 2022 on the MAGE-A4 program, builds upon the Company’s cell therapy development capabilities originally designed to more rapidly explore and validate T cell-based immunotherapy therapy products in Greater China. Additionally, the parties intend to add additional candidates in the future.

The Company will initiate process development and First-in-Human clinical trials in China and both parties will share the cost. Within a specified time period, the Company has an exclusive right to negotiate for an exclusive license of develop, manufacture and commercialize the product in Greater China. The Company will also be eligible to receive from 2seventy bio up to high double digit million US dollars development, regulatory and sales milestones, as well as potentially royalty payments on worldwide net sales, excluding Greater China pursuant to the Collaboration Agreement.

The Board considers that the Collaboration Agreement provides a valuable opportunity to the Company and 2seventy bio to leverage their respective resources and expertise and create mutual benefits and synergy to each other. Therefore, the Board is of the view that entering into the Collaboration Agreement is in the interest of the Company and its shareholders as a whole.

This announcement is made by the Company on a voluntary basis. The entering into Collaboration Agreement is of a revenue nature in the ordinary and usual course of business of the Company and does not constitute notifiable transaction under Chapter 14 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

About the AID program

The AID program is a natural extension of 2seventy bio's internal research and clinical expertise in developing CAR T cell therapies to target B cells and plasma cells, the key cell types that drive the pathobiology of autoimmune disorders. This drug product has been designed to achieve the necessary breadth and depth of target cell depletion to potentially provide a superior outcome for patients suffering from B cell driven autoimmune disease.

About JW Therapeutics

JW Therapeutics (Stock Code: 2126) is an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products. Since its founding in 2016, JW Therapeutics has built an integrated platform for product development in cell immunotherapy, as well as a product pipeline covering hematologic malignancies, solid tumors and autoimmune diseases. JW Therapeutics is committed to bringing breakthrough and quality cell immunotherapy products and the hope of a cure to patients in China and beyond, and to leading the healthy and standardized development of China's cell immunotherapy industry. For more information, please visit www.jwtherapeutics.com.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do — TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action — 270 miles per hour — to give the people we serve more time. We are building the leading immuno-oncology cell therapy company, focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. With a deep understanding of the human body's immune response to tumor cells and how to translate cell therapies into practice, we're applying this knowledge to deliver next generation cellular therapies that focus on a broad range of hematologic malignancies, including the first FDA-approved CAR T cell therapy for multiple myeloma, as well as solid tumors. Our research and development is focused on delivering therapies that are designed with the goal to "think" smarter and

faster than the disease. Importantly, we remain focused on accomplishing these goals by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: JW Therapeutics cannot guarantee that it will be able to develop, or ultimately market the Product successfully. The shareholders of the Company and investors are urged to exercise caution when dealings in the securities of the Company.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾(開曼)有限公司*
Yiping James Li
Chairman

Shanghai, PRC, January 2, 2024

As of the date of this announcement, the Board comprises Dr. Yiping James Li as Chairman and executive director; Ms. Xing Gao, Dr. Sungwon Song and Dr. Cheng Liu as non-executive directors, and Mr. Yiu Leung Andy Cheung, Mr. Kin Cheong Kelvin Ho, Dr. Debra Yu, Dr. Krishnan Viswanadhan and Dr. Ann Li Lee as independent non-executive directors.

* *For identification purposes only*